

Thymic Carcinoma

**A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma**

**Trial Status**  
Active, not recruiting

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT04321330 ML41253

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This is a phase II, open-label, single-arm, multicenter study of the efficacy and safety of atezolizumab treatment in participants with advanced thymic carcinoma who failed prior systemic therapy.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT04321330 ML41253**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---